Private Companies Among Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Private Companies Among Fujian Wanchen Biotechnology Group Co., Ltd.'s (SZSE:300972) Largest Stockholders and Were Hit After Last Week's 12% Price Drop
Key Insights
关键见解
- Significant control over Fujian Wanchen Biotechnology Group by private companies implies that the general public has more power to influence management and governance-related decisions
- 51% of the business is held by the top 3 shareholders
- Using data from company's past performance alongside ownership research, one can better assess the future performance of a company
- 私营公司对福建万晨生物科技集团的重大控制意味着公众拥有更大的影响管理和治理相关决策的权力
- 51% 的业务由前三名股东持有
- 使用公司过去业绩的数据以及所有权研究,可以更好地评估公司的未来表现
Every investor in Fujian Wanchen Biotechnology Group Co., Ltd. (SZSE:300972) should be aware of the most powerful shareholder groups. We can see that private companies own the lion's share in the company with 48% ownership. In other words, the group stands to gain the most (or lose the most) from their investment into the company.
福建万晨生物科技集团股份有限公司(深圳证券交易所代码:300972)的每位投资者都应了解最强大的股东群体。我们可以看到,私营公司拥有该公司的大部分股份,所有权为48%。换句话说,该集团将从对公司的投资中获得最多(或损失最大)。
As a result, private companies as a group endured the highest losses last week after market cap fell by CN¥645m.
结果,在市值下降6.45亿元人民币之后,私营公司作为一个整体承受了最大的损失。
Let's take a closer look to see what the different types of shareholders can tell us about Fujian Wanchen Biotechnology Group.
让我们仔细看看不同类型的股东能告诉我们关于福建万晨生物科技集团的哪些信息。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240202/0-60587822915c47988619f7b3ec2140f6-0-c1d9513953affb85a9217216465cf99a.png/big)
What Does The Institutional Ownership Tell Us About Fujian Wanchen Biotechnology Group?
关于福建万晨生物科技集团,机构所有权告诉我们什么?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见指数的回报进行比较。因此,他们通常会考虑收购相关基准指数中包含的大型公司。
We can see that Fujian Wanchen Biotechnology Group does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. It is not uncommon to see a big share price drop if two large institutional investors try to sell out of a stock at the same time. So it is worth checking the past earnings trajectory of Fujian Wanchen Biotechnology Group, (below). Of course, keep in mind that there are other factors to consider, too.
我们可以看到,福建万晨生物科技集团确实有机构投资者;他们持有该公司很大一部分股票。这可能表明该公司在投资界具有一定程度的信誉。但是,最好谨慎行事,不要依赖机构投资者所谓的验证。他们也是,有时候会弄错。如果两个大型机构投资者试图同时抛售股票,股价大幅下跌的情况并不少见。因此,值得查看福建万晨生物科技集团过去的收益轨迹(见下图)。当然,请记住,还有其他因素需要考虑。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240202/0-60587822915c47988619f7b3ec2140f6-1-7633ee04cf33d6b2a4f83495a5c27004.png/big)
We note that hedge funds don't have a meaningful investment in Fujian Wanchen Biotechnology Group. Looking at our data, we can see that the largest shareholder is Fujian Mimosa Agricultural Development Co., Ltd. with 26% of shares outstanding. In comparison, the second and third largest shareholders hold about 19% and 5.0% of the stock. Zening Wang, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.
我们注意到,对冲基金没有对福建万晨生物科技集团进行有意义的投资。从我们的数据来看,我们可以看到最大股东是福建含羞草农业发展有限公司,已发行股份的26%。相比之下,第二和第三大股东持有约19%和5.0%的股份。第三大股东王泽宁也恰好拥有董事会成员的头衔。
After doing some more digging, we found that the top 3 shareholders collectively control more than half of the company's shares, implying that they have considerable power to influence the company's decisions.
在进一步挖掘之后,我们发现前三名股东共同控制了公司一半以上的股份,这意味着他们拥有影响公司决策的巨大权力。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. While there is some analyst coverage, the company is probably not widely covered. So it could gain more attention, down the track.
虽然研究公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向哪个方向吹来也是有意义的。尽管有一些分析师的报道,但该公司的报道可能并不广泛。因此,在未来它可能会引起更多关注。
Insider Ownership Of Fujian Wanchen Biotechnology Group
福建万晨生物科技集团的内部所有权
The definition of an insider can differ slightly between different countries, but members of the board of directors always count. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
不同国家对内部人员的定义可能略有不同,但董事会成员总是计算在内。公司管理层经营业务,但首席执行官将向董事会负责,即使他或她是董事会成员。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常认为内部所有权是一件好事。但是,在某些情况下,这使其他股东更难追究董事会对决策的责任。
We can report that insiders do own shares in Fujian Wanchen Biotechnology Group Co., Ltd.. As individuals, the insiders collectively own CN¥241m worth of the CN¥4.8b company. This shows at least some alignment. You can click here to see if those insiders have been buying or selling.
我们可以报告,内部人士确实拥有福建万晨生物科技集团有限公司的股份。作为个人,内部人士共同拥有这家价值48亿元人民币的公司价值2.41亿元人民币。这至少显示出一定的对齐性。你可以点击这里查看这些内部人士是否在买入或卖出。
General Public Ownership
一般公有制
With a 37% ownership, the general public, mostly comprising of individual investors, have some degree of sway over Fujian Wanchen Biotechnology Group. While this group can't necessarily call the shots, it can certainly have a real influence on how the company is run.
福建万晨生物科技集团拥有 37% 的所有权,主要是个人投资者,在一定程度上对福建万晨生物科技集团有影响力。尽管这个群体不一定能做主,但它肯定会对公司的运作方式产生真正的影响。
Private Company Ownership
私人公司所有权
Our data indicates that Private Companies hold 48%, of the company's shares. It's hard to draw any conclusions from this fact alone, so its worth looking into who owns those private companies. Sometimes insiders or other related parties have an interest in shares in a public company through a separate private company.
我们的数据表明,私人公司持有该公司48%的股份。仅凭这一事实很难得出任何结论,因此值得研究谁拥有这些私营公司。有时,内部人士或其他关联方通过单独的私人公司对上市公司的股份拥有权益。
Next Steps:
后续步骤:
I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. Case in point: We've spotted 1 warning sign for Fujian Wanchen Biotechnology Group you should be aware of.
我觉得看看究竟谁拥有一家公司非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。一个很好的例子:我们发现了福建万晨生物科技集团的一个警告信号,你应该注意。
If you would prefer discover what analysts are predicting in terms of future growth, do not miss this free report on analyst forecasts.
如果你想了解分析师对未来增长的预测,千万不要错过这份关于分析师预测的免费报告。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注意:本文中的数字是使用过去十二个月的数据计算得出的,这些数据是指截至财务报表日期当月最后一天的12个月期间。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St的这篇文章本质上是笼统的。我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感型公司公告或定性材料。简而言之,华尔街没有持有任何上述股票的头寸。